Federation des caisses Desjardins du Quebec
Position in LEGN — Legend Biotech Corp
CIK 2022297
LEVIS, A8
Position in LEGN
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$46,352
+$44,453 QoQ
Shares Held
1,605
+1428.6% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#180
of 218 holders
Holding Since
Jun 2024
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in LEGN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Federation des caisses Desjardins du Quebec holds $61,128,046 across 154 Biotechnology names. LEGN ranks #46 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
20,094 | $9,981,291 | |
| 2 | ARGX |
Argenx SE
|
7,637 | $7,085,378 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
10,915 | $6,805,937 | |
| 4 | INCY |
Incyte Corp
|
57,354 | $6,501,647 | |
| 5 | RVMD |
Revolution Medicines, Inc.
|
16,951 | $3,174,581 | |
| 6 | MRNA |
Moderna, Inc.
|
41,572 | $2,911,286 | |
| 7 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
8,591 | $2,586,147 | |
| 8 | TECH |
BIO-TECHNE Corp
|
32,626 | $2,305,026 |
All Filings in LEGN
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $46,352 | 1,605 | Shares | Defined | 2026-08-14 | |
| 2026-03-31 | $1,899 | 105 | Shares | Defined | 2026-05-14 | |
| 2025-12-31 | $5,543 | 255 | Shares | Defined | 2026-02-12 | |
| 2025-09-30 | $8,250 | 253 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | $8,978 | 253 | Shares | Defined | 2025-08-14 | |
| 2025-03-31 | $15,336 | 452 | Shares | Defined | 2025-05-15 | |
| 2024-12-31 | $24,632 | 757 | Shares | Defined | 2025-02-14 | |
| 2024-09-30 | $36,887 | 757 | Shares | Defined | 2024-11-13 | |
| 2024-06-30 | $28,965 | 654 | Shares | Defined | 2024-08-14 | |
| No filing history on record for this holder in this stock. | ||||||